Skip Navigation

JNCI Journal of the National Cancer Institute 2001 93(7):552-553; doi:10.1093/jnci/93.7.552
© 2001 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Määttänen, L.
Right arrow Articles by Hakama, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Määttänen, L.
Right arrow Articles by Hakama, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 93, No. 7, 552-553, April 4, 2001
© 2001 Oxford University Press

BRIEF COMMUNICATION

Three-Year Results of the Finnish Prostate Cancer Screening Trial

Liisa Määttänen, Anssi Auvinen, Ulf-Håkan Stenman, Teuvo Tammela, Sakari Rannikko, Jussi Aro, Harri Juusela, Matti Hakama

Affiliations of authors: L. Määttänen, Finnish Cancer Registry, Helsinki, Finland; A. Auvinen, Tampere School of Public Health, University of Tampere, Finland; U.-H. Stenman, Department of Clinical Chemistry, Helsinki University Hospital; T. Tammela, Department of Urology, Tampere University Hospital; S. Rannikko, Department of Urology, Helsinki University Hospital; J. Aro, Department of Surgery, Helsinki City Hospital; H. Juusela, Department of Surgery, Jorvi Hospital, Espoo, Finland; M. Hakama, Finnish Cancer Registry and Tampere School of Public Health, University of Tampere.

Correspondence to: Liisa Määttänen, M.P.H., Finnish Cancer Registry, Liisankatu 21 B, 00170 Helsinki, Finland (e-mail: liisa.maattanen@cancer.fi).

Prostate cancer screening is increasing despite lack of demonstrated effectiveness (1). Large randomized, controlled trials with long-term follow-up are ongoing in Europe and North America to assess the effects of screening on mortality and quality of life (2).

The Finnish trial is a part of the European Randomized Study of Screening for Prostate Cancer, a multicenter trial with eight participating centers (3). The common core protocol includes enrollment of men at age 55–67 years and a screening test to assay the concentration of prostate-specific antigen (PSA) in serum, with a PSA cutoff point of 4.0 ng/mL.

We report here the attendance rate, the specificity, and the detection rate of prostate cancer during the first 3 years of the prevalence . . . [Full Text of this Article]

NOTES

REFERENCES


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Clin. Chem.Home page
L. Zhu, H. Koistinen, U. Landegren, and U.-H. Stenman
Proximity Ligation Measurement of the Complex between Prostate Specific Antigen and {alpha}1-Protease Inhibitor
Clin. Chem., September 1, 2009; 55(9): 1665 - 1671.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
P. Bono, A. Krause, M. von Mehren, M. C. Heinrich, C. D. Blanke, S. Dimitrijevic, G. D. Demetri, and H. Joensuu
Serum KIT and KIT ligand levels in patients with gastrointestinal stromal tumors treated with imatinib
Blood, April 15, 2004; 103(8): 2929 - 2935.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
H. Joensuu, A. Anttonen, M. Eriksson, R. Makitaro, H. Alfthan, V. Kinnula, and S. Leppa
Soluble Syndecan-1 and Serum Basic Fibroblast Growth Factor Are New Prognostic Factors in Lung Cancer
Cancer Res., September 15, 2002; 62(18): 5210 - 5217.
[Abstract] [Full Text] [PDF]